Alkermes Plc (ALKS)

Alkermes Plc experienced significant insider selling over the past ninety days, totaling nearly three million dollars. Executives including David Gaffin and Craig Hopkinson executed multiple planned divestments. These activities follow a strong stock performance and a positive earnings report. No insider purchases were recorded during this period, reflecting a trend of net liquidation by leadership.
Ticker: ALKS Exchange: NSM


Loading...
Purchase Sale Planned purchase Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Alkermes Plc. Upgrade to see score, net flow, insiders and the full signal context.

Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
2.7
snyderman nancy lynn MD Non-Executive Director
Transaction date
Sale
Price
427.99
Quantity 31,572 -44.4%
Value US$640,037
Hopkinson Craig C. EVP R&D, Chief Medical Officer Officer
Transaction date
Planned sale
Price
375.89
Quantity 48,763 +30.4%
Value US$3,789,386
Gaffin David Joseph EVP, CLO, Alkermes, Inc. Officer
Transaction date
Planned sale
Price
267.91
Quantity 8,298 +30.3%
Value US$3,088,332
2.7
snyderman nancy lynn MD Officer Officer
Transaction date
Proposed sale
Price
50.35
Quantity 1,000
Value US$100,000
Gaffin David Joseph Officer Officer
Transaction date
Proposed sale
Price
48.58
Quantity 1,000
Value US$100,000
Hopkinson Craig C. Officer Officer
Transaction date
Proposed sale
Price
48.58
Quantity 1,000
Value US$100,000
Gaffin David Joseph EVP, CLO, Alkermes, Inc. Officer
Transaction date
Planned sale
Price
54.03
Quantity 2,034 -0.9%
Value US$109,897
Gaffin David Joseph Officer Officer
Transaction date
Proposed sale
Price
54.03
Quantity 2,034
Value US$109,897
Hopkinson Craig C. EVP R&D, Chief Medical Officer Officer
Transaction date
Planned sale
Price
52.13
Quantity 700 -0.9%
Value US$36,492
Hopkinson Craig C. EVP R&D, Chief Medical Officer Officer
Transaction date
Planned sale
Price
51.46
Quantity 8,300 -10.1%
Value US$427,129
Hopkinson Craig C. Officer Officer
Transaction date
Proposed sale
Price
51.51
Quantity 9,000
Value US$463,621
Wright Christopher I Non-Executive Director
Transaction date
Planned sale
Price
45.10
Quantity 2,000 -7.2%
Value US$90,200
Wright Christopher I Officer Officer
Transaction date
Proposed sale
Price
45.10
Quantity 2,000
Value US$90,200
Gaffin David Joseph EVP, CLO, Alkermes, Inc. Officer
Transaction date
Planned sale
Price
43.05
Quantity 2,034 -0.9%
Value US$87,564
Gaffin David Joseph EVP, CLO, Alkermes, Inc. Officer
Transaction date
Planned sale
Price
43.05
Quantity 2,034 -0.9%
Value US$87,564
Gaffin David Joseph Officer Officer
Transaction date
Proposed sale
Price
43.05
Quantity 2,034
Value US$87,564
Hopkinson Craig C. EVP R&D, Chief Medical Officer Officer
Transaction date
Planned sale
Price
41.67
Quantity 9,000 -10.4%
Value US$375,044
Hopkinson Craig C. Officer Officer
Transaction date
Proposed sale
Price
41.67
Quantity 9,000
Value US$375,043
Hopkinson Craig C. Officer Officer
Transaction date
Proposed sale
Price
41.67
Quantity 9,000
Value US$375,043
2.5
Parisi Samuel Joseph VP, Finance (Interim PAO) Officer
Transaction date
Sale
Price
42.36
Quantity 16,217 -67.8%
Value US$687,007
Gaffin David Joseph EVP, CLO, Alkermes, Inc. Officer
Transaction date
Planned sale
Price
33.20
Quantity 2,034 -0.9%
Value US$67,529
Gaffin David Joseph Officer Officer
Transaction date
Proposed sale
Price
33.20
Quantity 2,034
Value US$67,529
Hopkinson Craig C. EVP R&D, Chief Medical Officer Officer
Transaction date
Planned sale
Price
33.40
Quantity 9,000 -10.0%
Value US$300,560
Hopkinson Craig C. Officer Officer
Transaction date
Proposed sale
Price
33.40
Quantity 9,000
Value US$300,560
Gaffin David Joseph EVP, CLO, Alkermes, Inc. Officer
Transaction date
Planned sale
Price
34.57
Quantity 2,034 -0.9%
Value US$70,315
Gaffin David Joseph Officer Officer
Transaction date
Proposed sale
Price
34.57
Quantity 2,034
Value US$70,315
Hopkinson Craig C. EVP R&D, Chief Medical Officer Officer
Transaction date
Planned sale
Price
35.51
Quantity 9,000 -9.5%
Value US$319,604
Hopkinson Craig C. Officer Officer
Transaction date
Proposed sale
Price
35.51
Quantity 9,000
Value US$319,604
Gaffin David Joseph EVP, CLO, Alkermes, Inc. Officer
Transaction date
Planned sale
Price
29.76
Quantity 2,034 -0.9%
Value US$60,532
Gaffin David Joseph Officer Officer
Transaction date
Proposed sale
Price
29.76
Quantity 2,034
Value US$60,532
2.5
Parisi Samuel Joseph VP, Finance (Interim PAO) Officer
Transaction date
Planned sale
Price
29.29
Quantity 6,890 -47.2%
Value US$201,808
Nichols Christian Todd SVP, Chief Commercial Officer Officer
Transaction date
Planned sale
Price
30.00
Quantity 6,000 -5.2%
Value US$180,000
Gaffin David Joseph EVP, CLO, Alkermes, Inc. Officer
Transaction date
Planned sale
Price
29.29
Quantity 2,034 -0.8%
Value US$59,576
Hopkinson Craig C. EVP R&D, Chief Medical Officer Officer
Transaction date
Planned sale
Price
29.72
Quantity 9,000 -9.1%
Value US$267,485
Nichols Christian Todd Officer Officer
Transaction date
Proposed sale
Price
30.00
Quantity 6,000
Value US$180,000
Gaffin David Joseph Officer Officer
Transaction date
Proposed sale
Price
29.29
Quantity 2,034
Value US$59,576
Hopkinson Craig C. Officer Officer
Transaction date
Proposed sale
Price
29.72
Quantity 9,000
Value US$267,485
3.3
Cooke Shane Officer Officer
Transaction date
Proposed sale
Price
34.57
Quantity 61,200
Value US$2,115,674
Hopkinson Craig C. Officer Officer
Transaction date
Proposed sale
Price
33.93
Quantity 9,000
Value US$305,384
Hopkinson Craig C. EVP R&D, Chief Medical Officer Officer
Transaction date
Planned sale
Price
33.54
Quantity 4,000 -6.5%
Value US$134,160
Hopkinson Craig C. EVP R&D, Chief Medical Officer Officer
Transaction date
Planned sale
Price
34.24
Quantity 5,000 -7.5%
Value US$171,224
3.3
Cooke Shane Non-Executive Director
Transaction date
Planned sale
Price
34.78
Quantity 32,113 -23.6%
Value US$1,116,877
3.3
Cooke Shane Non-Executive Director
Transaction date
Planned sale
Price
34.34
Quantity 29,087 -17.6%
Value US$998,795
Hopkinson Craig C. Officer Officer
Transaction date
Proposed sale
Price
30.00
Quantity 5,000
Value US$150,005
Hopkinson Craig C. EVP R&D, Chief Medical Officer Officer
Transaction date
Planned sale
Price
30.00
Quantity 5,000 -7.5%
Value US$150,005
Hopkinson Craig C. Officer Officer
Transaction date
Proposed sale
Price
28.00
Quantity 4,000
Value US$112,000
Hopkinson Craig C. EVP R&D, Chief Medical Officer Officer
Transaction date
Planned sale
Price
28.00
Quantity 4,000 -6.1%
Value US$112,000
Hopkinson Craig C. EVP R&D, Chief Medical Officer Officer
Transaction date
Planned sale
Price
30.00
Quantity 3,748 -5.4%
Value US$112,447
Hopkinson Craig C. Officer Officer
Transaction date
Proposed sale
Price
30.00
Quantity 3,748
Value US$112,447
Hopkinson Craig C. Officer Officer
Transaction date
Proposed sale
Price
29.30
Quantity 4,000
Value US$117,200
Hopkinson Craig C. EVP R&D, Chief Medical Officer Officer
Transaction date
Planned sale
Price
29.30
Quantity 4,000 -5.7%
Value US$117,200
Hopkinson Craig C. Officer Officer
Transaction date
Proposed sale
Price
30.38
Quantity 9,000
Value US$273,442
Hopkinson Craig C. EVP R&D, Chief Medical Officer Officer
Transaction date
Planned sale
Price
30.38
Quantity 9,000 -11.4%
Value US$273,442
Hopkinson Craig C. Officer Officer
Transaction date
Proposed sale
Price
31.53
Quantity 9,000
Value US$283,777
Hopkinson Craig C. EVP R&D, Chief Medical Officer Officer
Transaction date
Planned sale
Price
31.53
Quantity 9,000 -10.9%
Value US$283,776
Nichols Christian Todd Officer Officer
Transaction date
Proposed sale
Price
31.09
Quantity 3,334
Value US$103,654
Nichols Christian Todd SVP, Chief Commercial Officer Officer
Transaction date
Planned sale
Price
31.09
Quantity 3,334 -3.7%
Value US$103,654
Nichols Christian Todd SVP, Chief Commercial Officer Officer
Transaction date
Planned sale
Price
31.95
Quantity 3,333 -3.6%
Value US$106,489
Nichols Christian Todd Officer Officer
Transaction date
Proposed sale
Price
31.95
Quantity 3,333
Value US$106,489
2.5
Parisi Samuel Joseph VP, Finance (Interim PAO) Officer
Transaction date
Planned sale
Price
34.00
Quantity 1,938 -20.1%
Value US$65,892
2.5
Parisi Samuel Joseph VP, Finance (Interim PAO) Officer
Transaction date
Planned sale
Price
35.26
Quantity 3,743 -32.7%
Value US$131,978
2.5
Parisi Samuel Joseph VP, Finance (Interim PAO) Officer
Transaction date
Planned sale
Price
35.69
Quantity 1,327 -14.7%
Value US$47,361
Hopkinson Craig C. EVP R&D, Chief Medical Officer Officer
Transaction date
Planned sale
Price
36.02
Quantity 108,833 -65.3%
Value US$3,920,001
Hopkinson Craig C. EVP R&D, Chief Medical Officer Officer
Transaction date
Planned sale
Price
34.02
Quantity 35,586 -17.6%
Value US$1,210,696
Hopkinson Craig C. Officer Officer
Transaction date
Proposed sale
Price
35.53
Quantity 144,419
Value US$5,130,694
Hopkinson Craig C. EVP R&D, Chief Medical Officer Officer
Transaction date
Planned sale
Price
33.27
Quantity 33,108 -36.4%
Value US$1,101,470
Hopkinson Craig C. EVP R&D, Chief Medical Officer Officer
Transaction date
Planned sale
Price
32.69
Quantity 171,813 -65.4%
Value US$5,616,808
Hopkinson Craig C. Officer Officer
Transaction date
Proposed sale
Price
32.78
Quantity 204,921
Value US$6,718,276
Hopkinson Craig C. EVP R&D, Chief Medical Officer Officer
Transaction date
Planned sale
Price
32.05
Quantity 100,918 -69.5%
Value US$3,234,382
Hopkinson Craig C. Officer Officer
Transaction date
Proposed sale
Price
32.05
Quantity 100,918
Value US$3,234,380
LAURENCIN CATO T Director Non-Executive Director
Transaction date
Proposed sale
Price
31.85
Quantity 2,691
Value US$85,708
Hopkinson Craig C. Officer Officer
Transaction date
Proposed sale
Price
32.07
Quantity 61,151
Value US$1,961,404
LAURENCIN CATO T Non-Executive Director
Transaction date
Planned sale
Price
31.85
Quantity 2,691 -10.5%
Value US$85,708
Hopkinson Craig C. EVP R&D, Chief Medical Officer Officer
Transaction date
Planned sale
Price
32.07
Quantity 61,151 -56.2%
Value US$1,961,406
Hopkinson Craig C. Officer Officer
Transaction date
Proposed sale
Price
31.50
Quantity 9,221
Value US$290,462
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value
Number of shares Price Value Details
2026-08-03 2026-08-03 S Sale Non-Executive Director
31,572 -44.4%
427.99
US$640,037
31,572 -44.4% 427.99 US$640,037
2026-08-03 2026-08-03 PlS Planned sale

EVP R&D, Chief Medical Officer

Officer
48,763 +30.4%
375.89
US$3,789,386
48,763 +30.4% 375.89 US$3,789,386
2026-08-03 2026-08-03 PlS Planned sale

EVP, CLO, Alkermes, Inc.

Officer
8,298 +30.3%
267.91
US$3,088,332
8,298 +30.3% 267.91 US$3,088,332
2026-08-03 2026-08-03 PrS Proposed sale

Officer

Officer
1,000
50.35
US$100,000
1,000 50.35 US$100,000
2026-08-03 2026-08-03 PrS Proposed sale

Officer

Officer
1,000
48.58
US$100,000
1,000 48.58 US$100,000
2026-08-03 2026-08-03 PrS Proposed sale

Officer

Officer
1,000
48.58
US$100,000
1,000 48.58 US$100,000
2026-07-06 2026-07-06 PlS Planned sale

EVP, CLO, Alkermes, Inc.

Officer
2,034 -0.9%
54.03
US$109,897
2,034 -0.9% 54.03 US$109,897
2026-07-06 2026-07-06 PrS Proposed sale

Officer

Officer
2,034
54.03
US$109,897
2,034 54.03 US$109,897
2026-07-01 2026-07-01 PlS Planned sale

EVP R&D, Chief Medical Officer

Officer
700 -0.9%
52.13
US$36,492
700 -0.9% 52.13 US$36,492
2026-07-01 2026-07-01 PlS Planned sale

EVP R&D, Chief Medical Officer

Officer
8,300 -10.1%
51.46
US$427,129
8,300 -10.1% 51.46 US$427,129
2026-07-01 2026-07-01 PrS Proposed sale

Officer

Officer
9,000
51.51
US$463,621
9,000 51.51 US$463,621
2026-06-12 2026-06-12 PlS Planned sale Non-Executive Director
2,000 -7.2%
45.10
US$90,200
2,000 -7.2% 45.10 US$90,200
2026-06-12 2026-06-12 PrS Proposed sale

Officer

Officer
2,000
45.10
US$90,200
2,000 45.10 US$90,200
2026-06-04 2026-06-04 PlS Planned sale

EVP, CLO, Alkermes, Inc.

Officer
2,034 -0.9%
43.05
US$87,564
2,034 -0.9% 43.05 US$87,564
2026-06-04 2026-06-04 PlS Planned sale

EVP, CLO, Alkermes, Inc.

Officer
2,034 -0.9%
43.05
US$87,564
2,034 -0.9% 43.05 US$87,564
2026-06-04 2026-06-04 PrS Proposed sale

Officer

Officer
2,034
43.05
US$87,564
2,034 43.05 US$87,564
2026-06-01 2026-06-01 PlS Planned sale

EVP R&D, Chief Medical Officer

Officer
9,000 -10.4%
41.67
US$375,044
9,000 -10.4% 41.67 US$375,044
2026-06-01 2026-06-01 PrS Proposed sale

Officer

Officer
9,000
41.67
US$375,043
9,000 41.67 US$375,043
2026-06-01 2026-06-01 PrS Proposed sale

Officer

Officer
9,000
41.67
US$375,043
9,000 41.67 US$375,043
2026-05-29 2026-05-29 S Sale

VP, Finance (Interim PAO)

Officer
16,217 -67.8%
42.36
US$687,007
16,217 -67.8% 42.36 US$687,007
2026-05-04 2026-05-04 PlS Planned sale

EVP, CLO, Alkermes, Inc.

Officer
2,034 -0.9%
33.20
US$67,529
2,034 -0.9% 33.20 US$67,529
2026-05-04 2026-05-04 PrS Proposed sale

Officer

Officer
2,034
33.20
US$67,529
2,034 33.20 US$67,529
2026-05-01 2026-05-01 PlS Planned sale

EVP R&D, Chief Medical Officer

Officer
9,000 -10.0%
33.40
US$300,560
9,000 -10.0% 33.40 US$300,560
2026-05-01 2026-05-01 PrS Proposed sale

Officer

Officer
9,000
33.40
US$300,560
9,000 33.40 US$300,560
2026-04-06 2026-04-06 PlS Planned sale

EVP, CLO, Alkermes, Inc.

Officer
2,034 -0.9%
34.57
US$70,315
2,034 -0.9% 34.57 US$70,315
2026-04-06 2026-04-06 PrS Proposed sale

Officer

Officer
2,034
34.57
US$70,315
2,034 34.57 US$70,315
2026-04-01 2026-04-01 PlS Planned sale

EVP R&D, Chief Medical Officer

Officer
9,000 -9.5%
35.51
US$319,604
9,000 -9.5% 35.51 US$319,604
2026-04-01 2026-04-01 PrS Proposed sale

Officer

Officer
9,000
35.51
US$319,604
9,000 35.51 US$319,604
2026-03-04 2026-03-03 PlS Planned sale

EVP, CLO, Alkermes, Inc.

Officer
2,034 -0.9%
29.76
US$60,532
2,034 -0.9% 29.76 US$60,532
2026-03-03 2026-03-03 PrS Proposed sale

Officer

Officer
2,034
29.76
US$60,532
2,034 29.76 US$60,532
2026-03-04 2026-03-02 PlS Planned sale

VP, Finance (Interim PAO)

Officer
6,890 -47.2%
29.29
US$201,808
6,890 -47.2% 29.29 US$201,808
2026-03-04 2026-03-02 PlS Planned sale

SVP, Chief Commercial Officer

Officer
6,000 -5.2%
30.00
US$180,000
6,000 -5.2% 30.00 US$180,000
2026-03-04 2026-03-02 PlS Planned sale

EVP, CLO, Alkermes, Inc.

Officer
2,034 -0.8%
29.29
US$59,576
2,034 -0.8% 29.29 US$59,576
2026-03-04 2026-03-02 PlS Planned sale

EVP R&D, Chief Medical Officer

Officer
9,000 -9.1%
29.72
US$267,485
9,000 -9.1% 29.72 US$267,485
2026-03-02 2026-03-02 PrS Proposed sale

Officer

Officer
6,000
30.00
US$180,000
6,000 30.00 US$180,000
2026-03-02 2026-03-02 PrS Proposed sale

Officer

Officer
2,034
29.29
US$59,576
2,034 29.29 US$59,576
2026-03-02 2026-03-02 PrS Proposed sale

Officer

Officer
9,000
29.72
US$267,485
9,000 29.72 US$267,485
2026-02-02 2026-02-02 PrS Proposed sale

Officer

Officer
61,200
34.57
US$2,115,674
61,200 34.57 US$2,115,674
2026-02-02 2026-02-02 PrS Proposed sale

Officer

Officer
9,000
33.93
US$305,384
9,000 33.93 US$305,384
2026-02-02 2026-02-02 PlS Planned sale

EVP R&D, Chief Medical Officer

Officer
4,000 -6.5%
33.54
US$134,160
4,000 -6.5% 33.54 US$134,160
2026-02-02 2026-02-02 PlS Planned sale

EVP R&D, Chief Medical Officer

Officer
5,000 -7.5%
34.24
US$171,224
5,000 -7.5% 34.24 US$171,224
2026-02-02 2026-02-02 PlS Planned sale Non-Executive Director
32,113 -23.6%
34.78
US$1,116,877
32,113 -23.6% 34.78 US$1,116,877
2026-02-02 2026-02-02 PlS Planned sale Non-Executive Director
29,087 -17.6%
34.34
US$998,795
29,087 -17.6% 34.34 US$998,795
2026-01-08 2026-01-08 PrS Proposed sale

Officer

Officer
5,000
30.00
US$150,005
5,000 30.00 US$150,005
2026-01-08 2026-01-08 PlS Planned sale

EVP R&D, Chief Medical Officer

Officer
5,000 -7.5%
30.00
US$150,005
5,000 -7.5% 30.00 US$150,005
2026-01-02 2026-01-02 PrS Proposed sale

Officer

Officer
4,000
28.00
US$112,000
4,000 28.00 US$112,000
2026-01-02 2026-01-02 PlS Planned sale

EVP R&D, Chief Medical Officer

Officer
4,000 -6.1%
28.00
US$112,000
4,000 -6.1% 28.00 US$112,000
2025-12-05 2025-12-03 PlS Planned sale

EVP R&D, Chief Medical Officer

Officer
3,748 -5.4%
30.00
US$112,447
3,748 -5.4% 30.00 US$112,447
2025-12-03 2025-12-03 PrS Proposed sale

Officer

Officer
3,748
30.00
US$112,447
3,748 30.00 US$112,447
2025-12-01 2025-12-01 PrS Proposed sale

Officer

Officer
4,000
29.30
US$117,200
4,000 29.30 US$117,200
2025-12-01 2025-12-01 PlS Planned sale

EVP R&D, Chief Medical Officer

Officer
4,000 -5.7%
29.30
US$117,200
4,000 -5.7% 29.30 US$117,200
2025-11-03 2025-11-03 PrS Proposed sale

Officer

Officer
9,000
30.38
US$273,442
9,000 30.38 US$273,442
2025-11-03 2025-11-03 PlS Planned sale

EVP R&D, Chief Medical Officer

Officer
9,000 -11.4%
30.38
US$273,442
9,000 -11.4% 30.38 US$273,442
2025-10-15 2025-10-15 PrS Proposed sale

Officer

Officer
9,000
31.53
US$283,777
9,000 31.53 US$283,777
2025-10-15 2025-10-15 PlS Planned sale

EVP R&D, Chief Medical Officer

Officer
9,000 -10.9%
31.53
US$283,776
9,000 -10.9% 31.53 US$283,776
2025-06-10 2025-06-10 PrS Proposed sale

Officer

Officer
3,334
31.09
US$103,654
3,334 31.09 US$103,654
2025-06-10 2025-06-10 PlS Planned sale

SVP, Chief Commercial Officer

Officer
3,334 -3.7%
31.09
US$103,654
3,334 -3.7% 31.09 US$103,654
2025-06-10 2025-06-09 PlS Planned sale

SVP, Chief Commercial Officer

Officer
3,333 -3.6%
31.95
US$106,489
3,333 -3.6% 31.95 US$106,489
2025-06-09 2025-06-09 PrS Proposed sale

Officer

Officer
3,333
31.95
US$106,489
3,333 31.95 US$106,489
2025-02-28 2025-02-28 PlS Planned sale

VP, Finance (Interim PAO)

Officer
1,938 -20.1%
34.00
US$65,892
1,938 -20.1% 34.00 US$65,892
2025-02-25 2025-02-25 PlS Planned sale

VP, Finance (Interim PAO)

Officer
3,743 -32.7%
35.26
US$131,978
3,743 -32.7% 35.26 US$131,978
2025-02-20 2025-02-20 PlS Planned sale

VP, Finance (Interim PAO)

Officer
1,327 -14.7%
35.69
US$47,361
1,327 -14.7% 35.69 US$47,361
2025-02-14 2025-02-13 PlS Planned sale

EVP R&D, Chief Medical Officer

Officer
108,833 -65.3%
36.02
US$3,920,001
108,833 -65.3% 36.02 US$3,920,001
2025-02-14 2025-02-13 PlS Planned sale

EVP R&D, Chief Medical Officer

Officer
35,586 -17.6%
34.02
US$1,210,696
35,586 -17.6% 34.02 US$1,210,696
2025-02-13 2025-02-13 PrS Proposed sale

Officer

Officer
144,419
35.53
US$5,130,694
144,419 35.53 US$5,130,694
2025-02-14 2025-02-12 PlS Planned sale

EVP R&D, Chief Medical Officer

Officer
33,108 -36.4%
33.27
US$1,101,470
33,108 -36.4% 33.27 US$1,101,470
2025-02-14 2025-02-12 PlS Planned sale

EVP R&D, Chief Medical Officer

Officer
171,813 -65.4%
32.69
US$5,616,808
171,813 -65.4% 32.69 US$5,616,808
2025-02-12 2025-02-12 PrS Proposed sale

Officer

Officer
204,921
32.78
US$6,718,276
204,921 32.78 US$6,718,276
2025-01-31 2025-01-30 PlS Planned sale

EVP R&D, Chief Medical Officer

Officer
100,918 -69.5%
32.05
US$3,234,382
100,918 -69.5% 32.05 US$3,234,382
2025-01-30 2025-01-30 PrS Proposed sale

Officer

Officer
100,918
32.05
US$3,234,380
100,918 32.05 US$3,234,380
2024-12-09 2024-12-09 PrS Proposed sale

Director

Non-Executive Director
2,691
31.85
US$85,708
2,691 31.85 US$85,708
2024-12-09 2024-12-09 PrS Proposed sale

Officer

Officer
61,151
32.07
US$1,961,404
61,151 32.07 US$1,961,404
2024-12-09 2024-12-09 PlS Planned sale Non-Executive Director
2,691 -10.5%
31.85
US$85,708
2,691 -10.5% 31.85 US$85,708
2024-12-09 2024-12-09 PlS Planned sale

EVP R&D, Chief Medical Officer

Officer
61,151 -56.2%
32.07
US$1,961,406
61,151 -56.2% 32.07 US$1,961,406
2024-12-05 2024-12-05 PrS Proposed sale

Officer

Officer
9,221
31.50
US$290,462
9,221 31.50 US$290,462